Ophthalmic Compositions
An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid. The composition has a viscosity in the range from about 300 cp to about 1500 cp, and a total concentration of cations of less than about 50 mM. The ophthalmic composition is used to treat patients suffering from allergic conjunctivitis, and includes instructing a person suffering from ocular itching resulting from allergic conjunctivitis to administer once or twice daily in the form of one or more eye drops the aqueous ophthalmic composition described.
1 . An aqueous ophthalmic composition comprising loteprednol etabonate, and polyacryclic acid, wherein the composition has a viscosity in the range from about 300 cp to about 1500 cp, a total concentration of cations of less than about 50 mM, and the viscosity does not increase upon contact with surface ocular fluid.
2 . The composition of claim 1 wherein the viscosity is in the range of 1000 cp to about 1500 cp outside the eye.
3 . The composition of claim 1 further comprising 0.3 wt. % to 0.6 wt. % propylene glycol, 0.6 wt. % to 1 wt. % glycerin, or any combination thereof.
4 . The composition of claim 1 comprising 0.2-0.5% polycarbophil, 0.3-0.6% propylene glycol, 0.6-1% glycerin, 03-2% loteprednol etabonate and water, wherein all percentages are in percent by weight of the total composition.
5 . The composition of claim 1 comprising 0.3-0.4% polycarbophil, 0.4-0.5% propylene glycol, 0.6-1% glycerin, 0.1-0.2% loteprednol etabonate and water, wherein all percentages are in percent by weight of the total composition.
6 . The composition of claim 5 comprising 0.16% of loteprednol etabonate, wherein all percentages are in percent by weight of the total composition.
7 . A method of treating allergic conjunctivitis comprising instructing a person suffering from ocular itching resulting from allergic conjunctivitis to administer once or twice daily in the form of one or more eye drops an aqueous ophthalmic composition comprising loteprednol etabonate and polyacryclic acid, wherein the composition has a viscosity in the range from about 300 cp to about 1500 cp.
8 . The method of claim 7 wherein the viscosity of the composition is in the range of 1000 cp to about 1500 cp outside the eye.
9 . The method of claim 7 wherein the instructing a person suffering from ocular itching includes to administer the aqueous ophthalmic composition once daily in the morning or evening.
10 . The method of claim 7 wherein the composition comprises 0.3-2% loteprednol etabonate, 0.2-0.5% polycarbophil, 0.3-0.6% propylene glycol, 0.6-1% glycerin, and water, wherein all percentages are in percent by weight of the total composition.
11 . The method of claim 7 wherein the composition comprises 0.3-0.4% polycarbophil, 0.4-0.5% propylene glycol, 0.6-1% glycerin, 0.1-0.2% loteprednol etabonate and water, wherein all percentages are in percent by weight of the total composition.
12 . The method of claim 11 wherein the composition comprises 0.16% of loteprednol etabonate, wherein all percentages are in percent by weight of the total composition.
13 . The method of claim 7 wherein the composition has a total concentration of cations of less than about 50 mM.
14 . The method of claim 12 wherein the instructing a person to administer once or twice daily an aqueous ophthalmic composition comprising loteprednol etabonate and polyacryclic acid provides the patient with the same or greater relief of ocular itching than a comparable ophthalmic composition comprising 0.2% by weight loteprednol etabonate and having a viscosity of 3-10 cp and which is administered four times daily.